Literature DB >> 8361139

Lithium nephrotoxicity.

R G Walker1.   

Abstract

After nearly two decades of concern and controversy surrounding the long-term effects of lithium on the kidney, the fact that lithium is capable of causing a major disturbance in water balance, manifest as polyuria and secondary polydipsia, remains undisputed. A decreased urinary concentrating ability (nephrogenic diabetes insipidus) with a disturbed responsiveness of the distal nephron to the action of ADH (vasopressin) is demonstrable, and the symptoms are largely reversible on cessation of lithium or reduction of the dose. An acute histological lesion of the distal nephron, corresponding to the site of lithium inhibition of the action of ADH, and consisting of epithelial cellular swelling and glycogen deposition, also appears to be readily reversible. Of greater concern is the development of a progressive impairment of urinary concentrating ability in patients on long-term maintenance therapy--especially those with a history of acute lithium toxicity and those additionally treated with neuroleptics. This functional lesion is not always reversible, and the underlying renal histology is a chronic focal interstitial nephropathy. Interestingly, some psychiatric patients never exposed to lithium have demonstrated similar renal histology. There is very little evidence that stable maintenance lithium therapy, without episodes of acute intoxication, is associated with a reduction of glomerular filtration rate. Episodes of acute lithium intoxication are largely predictable, and therefore avoidable, provided appropriate precautions are taken. Patients with polyuria and impaired urinary concentrating ability are at increased risk of acute lithium toxicity because of excessive renal losses of fluid, and these symptoms should be treated in the first instance with dosage reduction.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8361139

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  10 in total

Review 1.  Just the berries: Nephrotoxic drugs.

Authors:  Tom Hewlett
Journal:  Can Fam Physician       Date:  2004-05       Impact factor: 3.275

2.  Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells.

Authors:  Yang Gao; Melissa J Romero-Aleshire; Qi Cai; Theodore J Price; Heddwen L Brooks
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-24

3.  Mice lacking mPGES-1 are resistant to lithium-induced polyuria.

Authors:  Zhanjun Jia; Haiping Wang; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-19

Review 4.  Drug Interactions with Lithium: An Update.

Authors:  Patrick R Finley
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.

Authors:  D Marples; S Christensen; E I Christensen; P D Ottosen; S Nielsen
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Lithium nephrotoxicity.

Authors:  Abed N Azab; Alla Shnaider; Yamima Osher; Dana Wang; Yuly Bersudsky; R H Belmaker
Journal:  Int J Bipolar Disord       Date:  2015-06-05

7.  A case of bipolar affective disorder and aspiration pneumonia.

Authors:  Alessandro Gerada; Gaetano Dell'erba
Journal:  Case Rep Psychiatry       Date:  2013-07-15

8.  The soluble (Pro) renin receptor does not influence lithium-induced diabetes insipidus but does provoke beiging of white adipose tissue in mice.

Authors:  Kevin T Yang; Fei Wang; Xiaohan Lu; Kexin Peng; Tianxin Yang; J David Symons
Journal:  Physiol Rep       Date:  2017-11

9.  The impact of long-term lithium treatment on renal function in an outpatient population.

Authors:  Sarah M McCann; James Daly; Christopher B Kelly
Journal:  Ulster Med J       Date:  2008-05

10.  The redox sensitive glycogen synthase kinase 3β suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury.

Authors:  Changbin Li; Yan Ge; Ai Peng; Rujun Gong
Journal:  Oncotarget       Date:  2015-11-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.